Introduction

Artificial intelligence has entered a new phase in pharmacovigilance. While early applications focused on automation for literature screening, case triage, and signal management, 2026 will mark the point where AI becomes both operationally indispensable and formally regulated.

The EU Artificial Intelligence Act is rolling out across industries, and the European Commission will release dedicated guidance on the responsible use of AI in pharmacovigilance and regulatory systems by Q4 2026. At the same time, AI tools are advancing quickly, taking on larger volumes of safety data, accelerating trend detection, and giving safety scientists more time for meaningful interpretation and decision-making.

Perspective Pharmacovigilance sees 2026 as a pivotal moment. As automation expands and expectations rise, sponsors will need to demonstrate transparency, oversight, and scientific governance in systems that increasingly rely on AI. PPV helps biopharma organizations prepare for this shift by integrating AI governance, validation, and operational readiness into safety frameworks.

AI Regulation Comes to Pharmacovigilance

The EU AI Action Plan is the first comprehensive framework to govern artificial intelligence across sectors, including healthcare. Key initiatives with direct relevance to pharmacovigilance include:

• Establishment of AI-powered screening centers across Europe by 2027
• Creation of European Networks of Expertise on AI in Healthcare
• An AI-driven drug discovery challenge supporting innovation for unmet needs
• Forthcoming EU guidance on the use of AI in pharmacovigilance and regulatory activities by late 2026

This guidance will define how AI tools must be validated, governed, monitored, and inspected under Good Pharmacovigilance Practices.

How AI Is Transforming Signal Detection

AI is reshaping signal detection in ways that help overstretched safety teams operate more effectively:

• Automation takes on the heavy lift of reviewing large volumes of safety data
• Scientists gain more time for interpretation, pattern recognition, and decision-making
• Teams can scale earlier without sacrificing quality or control

Even as tools improve, human oversight remains essential. Automated screening produces the best results when paired with the contextual judgment, governance, and experience that trained safety professionals bring.

At the same time, most AI adoption in PV today still centers on case intake, ICSR source data ingestion, and literature review. Movement into higher-risk activities like signal management is happening, but with far more caution and slower real-world adoption than many vendors claim.

For growing biotech companies, the opportunity is clear: build processes that move faster, stay compliant, and keep patient protection at the center.

Why This Matters for Drug Safety

AI brings both operational efficiency and new regulatory expectations. Sponsors will need to demonstrate that their AI tools are trustworthy, transparent, explainable, and aligned with scientific and ethical standards. Regulators will expect:

• Documented model validation
• Clear human oversight
• Traceability of data inputs and outputs
• Governance that protects data integrity and patient safety

The reality, however, is that the return on investment for AI tools varies widely. Many initiatives deliver incremental gains rather than the dramatic improvements often marketed- especially in smaller or fragmented PV environments where data interoperability remains a challenge. A balanced view acknowledges both AI’s long-term potential and its near-term limitations.

Companies that prepare now will be positioned to benefit from automation without compromising regulatory confidence.

Preparing for AI in Pharmacovigilance Systems

1. Integrate AI Readiness into PV System Design

AI should be incorporated into PV system design, not added after the fact. PPV supports clients with evaluating quality management systems, vendor oversight, and documentation workflows to ensure readiness for validated AI tools. This includes audit trail design, model validation processes, and documentation aligned with EMA, ISO, and GVP expectations.

2. Assess Algorithm Transparency and Auditability

Sponsors must be able to explain how AI-generated outputs are derived, particularly in signal detection, case processing, and trend analysis. PPV helps organizations evaluate vendor solutions for transparency, auditability, and compliance with the AI Act’s requirements for high-risk systems.

3. Build Inspection Readiness for AI Oversight

Regulators are preparing to inspect AI-enabled systems. Companies must demonstrate governance controls, validation evidence, and continuous performance monitoring. PPV helps teams build inspection readiness programs that include risk assessments, audit documentation, and governance frameworks designed for long-term oversight.

4. Strengthen Collaboration Across Functions

AI succeeds when data science, safety, and regulatory teams work together. Cross-functional alignment ensures AI enhances human judgment, maintains ethical standards, and supports sound decision-making. PPV helps teams establish governance models that integrate technical, scientific, and regulatory expertise.

Strategic Implications for Biopharma

AI will continue to reshape pharmacovigilance throughout 2026 and beyond. Strategic preparation includes:

• Updating SOPs to include AI governance and validation
• Evaluating vendors for compliance with the AI Act and GVP
• Establishing data governance and algorithm oversight frameworks
• Participating in industry and regulatory discussions on AI in drug safety

Early adopters will be better positioned to accelerate operations, strengthen regulatory relationships, and demonstrate scientific leadership.

Key Takeaways for Pharmacovigilance Leaders

• AI will transform PV through 2026. New regulatory standards and advancing tools will reshape safety operations.
• Signal detection is evolving rapidly. Automation accelerates review, but human oversight remains essential.
• Transparency and traceability will define compliance. Sponsors must understand and document how AI processes safety data.
• Preparation starts now. AI readiness should be embedded into quality systems, vendor oversight, and PV documentation.
• Cross-functional collaboration is critical. AI should enhance scientific judgment, not replace it.

Conclusion

Artificial intelligence is becoming a regulated and operational reality in pharmacovigilance. With the EU AI Act entering force and new guidance expected by late 2026, biopharma organizations must prepare for systems that require transparency, oversight, and ethical governance.

At the same time, the industry is still early in real-world adoption. Fragmented systems, inconsistent data maturity, and very modest ROI from first-generation AI tools mean progress will remain uneven across sponsors. Balanced, evidence-driven implement

Perspective Pharmacovigilance helps sponsors and marketing authorization holders integrate AI responsibly into safety systems by supporting governance, validation, operational implementation, and inspection readiness.  

Contact us to learn how PPV can support the planning and implementation of your AI strategy to meet emerging regulatory standards and strengthen safety decision-making.

‍